STOCK TITAN
  1. Home
  2. News
  3. YS

YS Biopharma Co., Ltd. Ordinary Shares - YS STOCK NEWS

Welcome to our dedicated page for YS Biopharma Co., Ltd. Ordinary Shares news (Ticker: YS), a resource for investors and traders seeking the latest updates and insights on YS Biopharma Co., Ltd. Ordinary Shares stock.

YS Biopharma Co., Ltd. (Nasdaq: YS) is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering next-generation vaccines and therapeutic biologics for infectious diseases and cancer. Operating in China, the United States, Singapore, and the Philippines, YS Biopharma leverages its proprietary PIKA® immunomodulating technology platform to create innovative solutions for diseases such as rabies, coronavirus, hepatitis B, influenza, and shingles.

The company recently announced changes to its board of directors and key strategic appointments within its wholly-owned subsidiaries in China. Notable changes include the resignation of Mr. Bo Tan and Mr. Shaojing Tong from the board and the appointment of Ms. Chunyuan Wu as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

YS Biopharma is also making significant strides in its financial performance, having fully repaid a $40,000,000 loan, which enhances its financial strength and flexibility. The company continues to advance its product pipeline, achieving positive interim results from a Phase 3 clinical trial of its PIKA Rabies Vaccine, which promises accelerated protection and a shorter regimen compared to conventional vaccines.

In terms of financial health, YS Biopharma reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024. Despite challenges such as supply chain disruptions, the company maintained strong market leadership in rabies vaccines in China, with an estimated double-digit year-over-year growth in product sales during the fourth quarter of fiscal 2024.

Additionally, the company's YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B virus (HBV) infection received clinical trial approval from the Philippine FDA, with a Phase I clinical trial set to begin in June 2024.

YS Biopharma recently announced it would change its legal name to LakeShore Biopharma Co., Ltd., effective May 28, 2024, to better align with its global market positioning. The company's ordinary shares and warrants will continue to trade on Nasdaq under the new ticker symbols 'LSB' and 'LSBPW', respectively.

For more detailed information, visit investor.ysbiopharma.com.

News

YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries

Rhea-AI Summary
YS Biopharma Co., Ltd. announces changes to its board of directors and key strategic appointments in China. Two directors resign, new appointments made within subsidiaries. The Board now consists of ten directors, including key members. Senior officers also appointed, outlining key roles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
32.03%
Tags
none
-
News

YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024

Rhea-AI Summary
YS Biopharma Co., Ltd. announces the results of its extraordinary general meeting held in Hong Kong. Shareholders voted in favor of resolutions including reaffirming directors, conducting an investigation, enhancing corporate governance, and removing a former chairperson.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.71%
Tags
none
-
News

YS Biopharma Announces Results of Extraordinary General Meeting and Responds to False Statements about the Meeting

Rhea-AI Summary
YS Biopharma Co., Ltd. announces results of extraordinary general meeting, with shareholders voting against removal of directors and election of new ones. The company warns against false statements by Mr. Yi Zhang and associates. Legal actions taken to restrain unauthorized actions by certain individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
News

/C O R R E C T I O N -- YS Biopharma Co., Ltd./

Rhea-AI Summary
YS Biopharma recently disclosed the outcomes of its Extraordinary General Meeting and addressed misleading claims. Shareholders approved key resolutions, including the election of new board members. The company refuted inaccurate statements and emphasized its commitment to transparency and shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
none
-
News

Shareholders Led by Yi Zhang Announce Successful Results of Removal of Directors and Election of New Directors of YS Biopharma Co., Ltd.

Rhea-AI Summary
YS Biopharma Co., Ltd. successfully held an Extraordinary General Meeting of Shareholders, resulting in the removal of several directors and the election of new board members. Yi Zhang, representing the Convening Shareholders, expressed gratitude for shareholder support and aims to focus on the company's business strategy for long-term value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.46%
Tags
management
-
News

YS Biopharma to Hold an Extraordinary General Meeting on February 22, 2024 pursuant to a Shareholder Requisition to Enhance Corporate Governance

Rhea-AI Summary
YS Biopharma Co., Ltd. receives a requisition for an extraordinary general meeting from APEX Prospect Limited, a shareholder holding over 10% of voting power, to address alleged misconduct by the former chairperson. The Board agrees to convene the meeting on February 22, 2024, to vote on resolutions regarding governance and management changes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
none
News

YS Biopharma Announces Appointment of New Directors

Rhea-AI Summary
YS Biopharma Co., Ltd. appoints six new members to its Board of Directors, including Dr. Yuntao Cui, Dr. Jin Wang, Mr. Henry Chen, Mr. Haitao Zhao, Mr. Pierson Yue Pan, and Ms. Brenda Chunyuan Wu. Dr. Ajit Shetty elected as Chairperson of the Board. The new directors bring expertise in law, finance, real estate, and biotech industries, enhancing the company's governance and strategic decision-making.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
management
-
News

YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd.

Rhea-AI Summary
YS Biopharma Co., Ltd. issues an official response to the notice of an extraordinary general meeting of shareholders. The Convening Shareholders aim to remove six directors and appoint four new ones. The Company questions the validity of the EGM due to insufficient notice and lack of notice to directors proposed for removal. A recent private placement transaction has increased the outstanding ordinary shares. Shareholders are advised to seek legal advice.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.63%
Tags
none
-
News

YS Biopharma Announces US$40 Million Private Placement Financing

Rhea-AI Summary
YS Biopharma Co., Ltd. announced a $40 million private placement of 95,269,762 ordinary shares at $0.41986 per share, strengthening its balance sheet and supporting business growth. The transaction was exempt from registration requirements under the Securities Act of 1933 and followed the dismissal of an injunction order.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none
News

Shareholders of YS Biopharma Announce an Extraordinary General Meeting

Rhea-AI Summary
YS Biopharma Co., Ltd. announced the convening of an extraordinary general meeting of shareholders to remove six current members of the board of directors and elect four new directors. The meeting will be held on February 16, 2024, with Yi Zhang, the founder of YS Biopharma, being the Convening Shareholder. Shareholders of record as of February 8, 2024, are entitled to vote at the EGM.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
none

FAQ

What is the current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The current stock price of YS Biopharma Co., Ltd. Ordinary Shares (YS) is $1.02 as of May 24, 2024.

What is the market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS)?

The market cap of YS Biopharma Co., Ltd. Ordinary Shares (YS) is approximately 192.1M.

What does YS Biopharma specialize in?

YS Biopharma specializes in discovering, developing, manufacturing, and delivering vaccines and therapeutic biologics for infectious diseases and cancer.

Where does YS Biopharma operate?

YS Biopharma operates in China, the United States, Singapore, and the Philippines.

What is the PIKA® technology platform?

The PIKA® technology platform is YS Biopharma's proprietary immunomodulating technology used to develop next-generation vaccines and biologics.

What recent changes have been made to the board of directors?

Mr. Bo Tan and Mr. Shaojing Tong have resigned from the board, and Ms. Chunyuan Wu has been appointed as the new legal representative and executive director of Beijing Yisheng Biotechnology Co., Ltd.

What are the latest financial achievements of YS Biopharma?

YS Biopharma recently fully repaid a $40,000,000 loan and reported revenues of RMB438.1 million ($61.9 million) for the first nine months of fiscal 2024.

What are the key products in YS Biopharma's pipeline?

Key products include the PIKA Rabies Vaccine, PIKA YS-ON-001, and the YS-HBV-002 immunotherapeutic vaccine for chronic hepatitis B.

Has YS Biopharma received any recent regulatory approvals?

Yes, YS Biopharma's YS-HBV-002 vaccine received clinical trial approval from the Philippine FDA.

What is the new name of YS Biopharma?

The new name of YS Biopharma is LakeShore Biopharma Co., Ltd.

Will the ticker symbol of YS Biopharma change?

Yes, the ticker symbol will change to 'LSB' for ordinary shares and 'LSBPW' for warrants, effective May 28, 2024.

How can I get more information about YS Biopharma?

For more information, visit the company's investor relations website at investor.ysbiopharma.com.

Stock YS logo
YS Biopharma Co., Ltd. Ordinary Shares

Nasdaq:YS

YS Rankings

#3882 Ranked by Market Cap
N/A Ranked by Dividends

YS Stock Data

192.09M
188.33M
81.43%
2.85%
0.02%
Biotechnology
Healthcare
Link
United States of America
Beijing